Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00630877 · ClinicalTrials.gov registry record · Phase 3
Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 276
- Enrollment target
NCT00630877 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 276 participants.
The verdict
NCT00630877, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 276 participants
- Enrollment target
Study Summary
The primary purpose of this study was to evaluate the psychometric characteristics (reliability, validity, and responsiveness) of a Flushing ASsessment Tool (FAST) in subjects receiving niacin extended-release (NER) plus aspirin (ASA) daily for 6 weeks. The FAST is a questionnaire that was developed to provide a detailed assessment of flushing symptoms and their impact in patients receiving niacin therapy. The effect of aspirin on flushing symptoms, as measured by the FAST, was also evaluated.
Interventions
- DRUG Niacin extended-release (NER)
- DRUG Niacin extended-release (NER) placebo
- DRUG Aspirin (ASA)
- DRUG Aspirin (ASA) placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00630877
The ClinicalTrials.gov registry entry for NCT00630877 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Niacin extended-release (NER) is the first listed.
NCT00630877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00630877 about?
NCT00630877 is a clinical study titled "Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin". The primary purpose of this study was to evaluate the psychometric characteristics (reliability, validity, and responsiveness) of a Flushing ASsessment Tool (FAST) in subjects receiving niacin extended-release (NER) plus aspirin (ASA) daily for 6 weeks. The FAST is a questionnaire that was develope...
What is the current status of trial NCT00630877?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 276 participants. The study started on 2008-02. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00630877?
The interventions under investigation include: Niacin extended-release (NER) (DRUG), Niacin extended-release (NER) placebo (DRUG), Aspirin (ASA) (DRUG), Aspirin (ASA) placebo (DRUG).
Who is sponsoring clinical trial NCT00630877?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.